Abstract
A major challenge in the development of oligonucleotide-based microRNA (miRNA) inhibitors for therapeutic applications is the identification of candidate designs with strong affinity for the target miRNA in the context of the Argonaute complex. To this effect, distinct chemical modifications are employed along the length of the oligonucleotide aimed at strengthening the interactions with the target miRNA. However, the modification chemistry and placement can inadvertently affect the intrinsic ability of the oligonucleotide to pair with its target in the context of Argonaute. To facilitate the design of potent oligonucleotides, we developed a sensitive high-throughput methodology to compare anti-miR compounds for their ability to associate with the miRNA/Argonaute complex.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Mendell JT, Olson EN (2012) MicroRNAs in stress signaling and human disease. Cell 148:1172–1187
Seyhan AA (2015) microRNAs with different functions and roles in disease development and as potential biomarkers of diabetes: progress and challenges. Mol Biosyst 11:1217–1234
Chi SW, Zang JB, Mele A, Darnell RB (2009) Argonaute HITS-CLIP decodes microRNA-mRNA interaction maps. Nature 460:479–486
Zisoulis DG, Lovci MT, Wilbert ML, Hutt KR, Liang TY et al (2010) Comprehensive discovery of endogenous Argonaute binding sites in Caenorhabditis elegans. Nature structural & molecular biology 17:173–179
Hutvagner G, Simard MJ, Mello CC, Zamore PD (2004) Sequence-specific inhibition of small RNA function. PLoS biology 2, E98
Meister G, Landthaler M, Dorsett Y, Tuschl T (2004) Sequence-specific inhibition of microRNA- and siRNA-induced RNA silencing. RNA 10:544–550
Jopling CL, Yi M, Lancaster AM, Lemon SM, Sarnow P (2005) Modulation of hepatitis C virus RNA abundance by a liver-specific MicroRNA. Science 309:1577–1581
Krützfeldt J, Rajewsky N, Braich R, Rajeev KG, Tuschl T et al (2005) Silencing of microRNAs in vivo with ‘antagomirs’. Nature 438:685–689
Davis S, Lollo B, Freier S, Esau C (2006) Improved targeting of miRNA with antisense oligonucleotides. Nucleic acids research 34:2294–2304
Esau C, Davis S, Murray SF, Yu XX, Pandey SK et al (2006) miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting. Cell metabolism 3:87–98
Janssen HL, Kauppinen S, Hodges MR (2013) HCV infection and miravirsen. N Engl J Med 369:878
Janssen HL, Reesink HW, Lawitz EJ, Zeuzem S, Rodriguez-Torres M et al (2013) Treatment of HCV infection by targeting microRNA. N Engl J Med 368:1685–1694
Van Der Ree MLV, Stelma F, Willemse S, van der Valk M, Rietdijk S, Molenkamp R, Schinkel J et al (2015) A single subcutaneous dose of 2 mg/kg or 4 mg/kg of RG-101, a GalNAc-conjugated oligonucleotide with antagonist activity against MIR-122, results in significant viral load reductions in chronic hepatitis C patients. Journal of Hepatology 62:261
Bartel DP (2009) MicroRNAs: target recognition and regulatory functions. Cell 136:215–233
Breda J, Rzepiela AJ, Gumienny R, van Nimwegen E, Zavolan M (2015) Quantifying the strength of miRNA-target interactions. Methods 85:90–9
Hammell M, Long D, Zhang L, Lee A, Carmack CS et al (2008) mirWIP: microRNA target prediction based on microRNA-containing ribonucleoprotein-enriched transcripts. Nat Methods 5:813–819
Esau CC (2008) Inhibition of microRNA with antisense oligonucleotides. Methods 44:55–60
Stenvang J, Petri A, Lindow M, Obad S, Kauppinen S (2012) Inhibition of microRNA function by antimiR oligonucleotides. Silence 3:1
Crooke ST (2008) Antisense drug technology: principles, strategies, and applications. CRC Press, Boca Raton, FL, xvii, 825 p, 812 p. of plates p
Hogan DJ, Vincent TM, Fish S, Marcusson EG, Bhat B et al (2014) Anti-miRs competitively inhibit microRNAs in Argonaute complexes. PLoS One 9, e100951
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2017 Springer Science+Business Media New York
About this protocol
Cite this protocol
Zisoulis, D.G. (2017). Quantification of Oligonucleotide Association with miRNA–Argonaute Complexes In Vitro. In: Schmidt, M. (eds) Drug Target miRNA. Methods in Molecular Biology, vol 1517. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-6563-2_4
Download citation
DOI: https://doi.org/10.1007/978-1-4939-6563-2_4
Published:
Publisher Name: Humana Press, New York, NY
Print ISBN: 978-1-4939-6561-8
Online ISBN: 978-1-4939-6563-2
eBook Packages: Springer Protocols